Press Releases

More than 40 million Americans gain access to Biocept's liquid biopsy tests through the FedMed National Provider NetworkBiocept increases coverage to more than 180 million PPO consumers

SAN DIEGO , March 7, 2016 /PRNewswire/ --  Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W.

Presentation to focus on Biocept's unique, patented technology to capture a broad range of CTCs leading to clinical applications and utility

Revenue-producing sample volume during 2015 increases by more than 30% each consecutive quarter to greater than 1,800 for the year

SAN DIEGO , Feb. 29, 2016 /PRNewswire/ --  Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the three months and 12 months

Increases coverage to approximately 140 million PPO consumers

Clinically validated data demonstrate greater than 93% concordance in detecting EGFR mutation with tissue biopsy in 74 patients diagnosed with lung cancer

SAN DIEGO , Feb. 2, 2016 /PRNewswire/ --  Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at

SAN DIEGO , Jan. 25, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO Michael W.

More than eight million members gain access to Biocept's suite of blood-based diagnostics through agreement with Illinois' largest health plan, bringing total covered lives to approximately 133 million